Celularity Inc - Ordinary Shares - Class A

+0.03 (+4.80%)
: $0.70 -0.06 (-7.73%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)143.85M
Current PE11.03
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.9 Million
Adjusted EPS-$0.23
See more estimates
10-Day MA$0.67
50-Day MA$0.62
200-Day MA$1.39
See more pivots

Celularity Inc - Ordinary Shares - Class A Stock, NASDAQ:CELU

170 Park Avenue, Florham Park, New Jersey 07932
United States of America
Phone: +1.908.768.2170
Number of Employees: 225


Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.